跳至主要内容
临床试验/EUCTR2011-000833-35-IT
EUCTR2011-000833-35-IT进行中(未招募)不适用

A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.

OVARTIS PHARMA AG0 个研究点目标入组 70 人开始时间: 2012年2月27日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients admitted to hospital or who require admission to hospital for management of acute heart failure with shortness of breath at rest or minimal exertion - stabilized within 2 days after admission - normal or elevated systolic blood pressure - elevated pulmonary capilary wedge pressure measured by Swan-Ganz catheterization
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 35

排除标准

  • - severe renal impairment - significant liver impairment - significant lung impairment - significant heart valve dysfunction or arrythmias - myocardial infarction or acute coronary syndrome within th elast 45 days

研究者

相似试验

进行中(未招募)
不适用
Hemodynamic responses to intravenous RLX030 infusion in patients with acute heart failureAcute Heart Failure
EUCTR2011-000833-35-DEovartis Pharma Services AG70
进行中(未招募)
不适用
Hemodynamic responses to intravenous RLX030 infusion in patients with acute heart failureMedDRA version: 14.1Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersAcute Heart Failure
EUCTR2011-000833-35-NLovartis Pharma Services AG70
招募中
2 期
A clinical study of norketotifen capsule 4 mg in the treatment patients with mild to moderate atopic dermatitis.
CTRI/2024/02/062891Bridge Pharma Inc
进行中(未招募)
1 期
Phase 2 trial, conducted in more than one site, in which no one knows the treatment assigned to the patient to evaluate the effect against pain and the safety of of the study drug, DFL24412, respect a control drug (Ketoprofen Lysine Salt, in patient with chronic low back paiChronic Low Back PainMedDRA version: 21.0Level: LLTClassification code 10052430Term: Chronic lumbagoSystem Organ Class: 100000004859
EUCTR2021-001629-38-ITDOMPé FARMACEUTICI S.P.A.150
进行中(未招募)
1 期
Phase 2 trial, conducted in more than one site, in which no one knows the treatment assigned to the patient to evaluate the effect against pain and the safety of the study drug, DFL24412, respect a control drug (Ketoprofen Lysine Salt), in patient with chronic low back paiChronic Low Back PainMedDRA version: 21.0Level: LLTClassification code 10052430Term: Chronic lumbagoSystem Organ Class: 100000004859
EUCTR2021-001629-38-ESDompè Farmaceutici S.p.A.150